Therapy Directory

Pembrolizumab clinical trials

Directory of U.S. ClinicalTrials.gov public records that list Pembrolizumab as a study intervention. Browse Pembrolizumab recruiting trials, filter by phase, sponsor, or location, and open the official ClinicalTrials.gov study record for each result.

ClinicalTrials.gov public records Last synced Nov 6, 2026, 12:50 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Official matching trials

1852

Shown on this page

Current sort

Live official records

Open in full search

Conditions: Cancer
Interventions: LVGN6051, KEYTRUDA® (pembrolizumab); Biological
Lead sponsor: Lyvgen Biopharma Holdings Limited; Industry
Eligibility: 18 Years and older
Enrollment: 105 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2025
U.S. locations: 7
States / cities: Orange, California • San Francisco, California • Lafayette, Indiana + 4 more

Conditions: Endometrial Cancer
Interventions: DKN-01, Pembrolizumab; Drug
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 8 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2029
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Ovarian Cancer
Interventions: Pembrolizumab, Bevacizumab, Cyclophosphamide; Drug
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years and older · Female only
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2027
U.S. locations: 2
States / cities: New York, New York • Houston, Texas

Conditions: Prostate Cancer, Radical Prostatectomy
Interventions: Microdevice; Combination Product
Lead sponsor: Brigham and Women's Hospital; Other
Eligibility: 22 Years and older · Male only
Enrollment: 35 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2027
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Renal Cell Carcinoma, Metastatic Renal Cell Carcinoma, Kidney Cancer
Interventions: Implantable Microdevice (IMD); Combination Product
Lead sponsor: Oliver Jonas; Other
Eligibility: 18 Years and older
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2029
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Muscle Invasive Bladder Urothelial Carcinoma
Interventions: Implantable Micro-Device, Methotrexate, Carboplatin, Avelumab, Paclitaxel, Vinblastine, Gemcitabine/Cisplatin I, Methotrexate/Vinblastine/Doxorubicin/Cisplatin/Avelumab, Gemcitabine/Cisplatin II, Cisplatin, Nivolumab, Pembrolizumab, Gemcitabine/Carboplatin, Methotrexate/Vinblastine/Doxorubicin/Cisplatin, Gemcitabine/Cisplatin/Nivolumab, Erdafitinib, Paclitaxel/Docetaxel/Ifosfamide, Gemcitabine, Gemcitabine/Carboplatin/Nivolumab, Enfortumab, Sacituzumab; Device · Drug
Lead sponsor: Brigham and Women's Hospital; Other
Eligibility: 18 Years to 120 Years
Enrollment: 18 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2028
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Hodgkin Lymphoma, Diffuse Large B Cell Lymphoma, Peripheral T-Cell Lymphoma
Interventions: Pembrolizumab; Drug
Lead sponsor: Dana-Farber Cancer Institute; Other
Eligibility: 18 Years and older
Enrollment: 82 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2023
U.S. locations: 6
States / cities: Duarte, California • Boston, Massachusetts • New York, New York + 1 more

Conditions: Advanced Lung Non-Small Cell Carcinoma, Recurrent Lung Non-Small Cell Carcinoma, Stage III Lung Cancer AJCC v8, Stage IIIA Lung Cancer AJCC v8, Stage IIIB Lung Cancer AJCC v8, Stage IIIC Lung Cancer AJCC v8, Stage IV Lung Cancer AJCC v8, Stage IVA Lung Cancer AJCC v8, Stage IVB Lung Cancer AJCC v8
Interventions: Cobalamin, Dexamethasone, Docetaxel, Folic Acid, Gemcitabine, Nogapendekin Alfa, Pembrolizumab, Pemetrexed, Ramucirumab; Dietary Supplement · Drug · Biological
Lead sponsor: SWOG Cancer Research Network; Network
Eligibility: Not listed
Enrollment: 82 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2027
U.S. locations: 350
States / cities: Birmingham, Alabama • Goodyear, Arizona • Little Rock, Arkansas + 280 more

Conditions: Hodgkin's Lymphoma
Interventions: Azacytidine, Pembrolizumab; Drug
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 1 Year and older
Enrollment: 24 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2026
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Prostate Cancer, Neuroendocrine Tumors, Small Cell Carcinoma
Interventions: BXCL701 plus Pembrolizumab, BXCL701 monotherapy; Drug
Lead sponsor: BioXcel Therapeutics Inc; Industry
Eligibility: 18 Years and older · Male only
Enrollment: 98 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2025
U.S. locations: 9
States / cities: San Francisco, California • Denver, Colorado • New Haven, Connecticut + 6 more

Conditions: Advanced or Metastatic NSCLC
Interventions: Datopotamab deruxtecan, KEYTRUDA®, Carboplatin, Cisplatin; Drug
Lead sponsor: Daiichi Sankyo; Industry
Eligibility: 18 Years and older
Enrollment: 145 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2026
U.S. locations: 9
States / cities: Scottsdale, Arizona • Duarte, California • Washington D.C., District of Columbia + 5 more

Conditions: Metastatic Melanoma, Squamous Cell Carcinoma of the Head and Neck, Non-small Cell Lung Cancer
Interventions: Lifileucel, LN-145, Pembrolizumab, LN-145-S1, Ipilimumab, Nivolumab, Nivolumab-relatlimab, Cisplatin, Carboplatin, Paclitaxel, Nab paclitaxel, Pemetrexed; Biological · Drug
Lead sponsor: Iovance Biotherapeutics, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 225 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2026
U.S. locations: 20
States / cities: La Jolla, California • Los Angeles, California • Denver, Colorado + 15 more

About this Pembrolizumab clinical trials directory page

What this page lists: U.S. ClinicalTrials.gov public records that list Pembrolizumab as a study intervention, including recruiting, not yet recruiting, and active not recruiting trials.
How to narrow results: Use the filters above to scope by condition, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, age, or NCT ID within Pembrolizumab.
Where the data comes from: Records are sourced from the official ClinicalTrials.gov public API. Each result links back to the official study page, which is the source of truth for eligibility, enrollment, and contact information.
What this page does not do: No medical advice, eligibility judgments, treatment recommendations, ranking of trials by quality, or AI-generated medical summaries.

Pembrolizumab clinical trials

Filter and sort this therapy

Live official records

Phase 1 Trial of LVGN6051 as Single Agent and in Combination With Keytruda (Pembrolizumab) in Advanced or Metastatic Malignancy

Phase 2 Study Evaluating the Efficacy of the Combination of DKN-01 (DKK1 Inhibitor, Leap Therapeutics) and Pembrolizumab in the Treatment of Advanced or Recurrent Endometrial Cancer

Phase II Investigation of Pembrolizumab in Combination With Bevacizumab and Oral Cyclophosphamide in Patients With High Grade Ovarian Cancer and Surgically Documented Minimal Residual Disease After Frontline Therapy

Pilot Study of an Implantable Microdevice for Evaluating Drug Responses in Situ in Prostate Cancer

Drug Screening Using Novel IMD in Renal Cell Carcinoma

Drug Screening Using IMD in Bladder Cancer

Pembrolizumab After ASCT for Hodgkin Lymphoma, DLBCL and T-NHL

Testing the Use of Combination Immunotherapy Treatment (N-803 [ALT-803] Plus Pembrolizumab) Against the Usual Treatment for Advanced Non-small Cell Lung Cancer (A Lung-MAP Treatment Trial)

A Phase II Study of the Combination of Azacitidine and Pembrolizumab for Patients Relapsed/Refractory Hodgkin's Lymphoma

A Trial of BXCL701 and Pembrolizumab in Patients With mCRPC Either Small Cell Neuroendocrine Prostate Cancer or Adenocarcinoma Phenotype.

Datopotamab Deruxtecan (Dato-DXd) in Combination With Pembrolizumab With or Without Platinum Chemotherapy in Subjects With Advanced or Metastatic Non-Small Cell Lung Cancer (TROPION-Lung02)

Study of Autologous Tumor Infiltrating Lymphocytes in Patients With Solid Tumors

About this Pembrolizumab clinical trials directory page